Icosavax, Inc. Stock News

Does Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Icosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine

Icosavax (NASDAQ: ICVX ) stock is rising higher on Tuesday after announcing a major acquisition deal with AstraZeneca (NASDAQ: AZN ). According to a press release, AstraZeneca is acquiring Icosavax 

Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million ca

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-

AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion.  The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (RSV

Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.

The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, th

Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines again

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

Icosavax also initiated a $67.8 million stock sale. The biopharmaceutical company's pipeline also includes vaccines to treat influenza and severe acute respiratory syndrome coronavirus.

Icosavax (ICVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.